JP2007529536A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007529536A5 JP2007529536A5 JP2007504018A JP2007504018A JP2007529536A5 JP 2007529536 A5 JP2007529536 A5 JP 2007529536A5 JP 2007504018 A JP2007504018 A JP 2007504018A JP 2007504018 A JP2007504018 A JP 2007504018A JP 2007529536 A5 JP2007529536 A5 JP 2007529536A5
- Authority
- JP
- Japan
- Prior art keywords
- calicheamicin
- conjugate
- acid
- derivative
- igg1 antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CC(*C(*)=O)C(CCC1C(C(C(C)(CCC(C2)=*)C2C2=*)C3=*)C2=*)C1(C)C3=* Chemical compound CC(*C(*)=O)C(CCC1C(C(C(C)(CCC(C2)=*)C2C2=*)C3=*)C2=*)C1(C)C3=* 0.000 description 3
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55311204P | 2004-03-15 | 2004-03-15 | |
| PCT/US2005/008508 WO2005089808A2 (en) | 2004-03-15 | 2005-03-15 | Antibody calicheamicin conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007529536A JP2007529536A (ja) | 2007-10-25 |
| JP2007529536A5 true JP2007529536A5 (enExample) | 2008-05-01 |
Family
ID=34962653
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007504018A Withdrawn JP2007529536A (ja) | 2004-03-15 | 2005-03-15 | 抗体カリケアマイシン結合体 |
| JP2007504017A Withdrawn JP2007529535A (ja) | 2004-03-15 | 2005-03-15 | 受動的ターゲティングのための抗体カリケアマイシン結合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007504017A Withdrawn JP2007529535A (ja) | 2004-03-15 | 2005-03-15 | 受動的ターゲティングのための抗体カリケアマイシン結合体 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20070213511A1 (enExample) |
| EP (3) | EP1725265A2 (enExample) |
| JP (2) | JP2007529536A (enExample) |
| KR (1) | KR20060130737A (enExample) |
| CN (2) | CN1997397A (enExample) |
| AR (1) | AR048098A1 (enExample) |
| AU (3) | AU2005222635A1 (enExample) |
| BR (2) | BRPI0508824A (enExample) |
| CA (3) | CA2559658A1 (enExample) |
| CR (1) | CR8620A (enExample) |
| EC (1) | ECSP066851A (enExample) |
| GT (1) | GT200500054A (enExample) |
| IL (1) | IL177842A0 (enExample) |
| MX (2) | MXPA06010556A (enExample) |
| NO (1) | NO20064128L (enExample) |
| PA (1) | PA8626201A1 (enExample) |
| PE (1) | PE20060077A1 (enExample) |
| RU (1) | RU2006131599A (enExample) |
| SV (1) | SV2006002050A (enExample) |
| TW (1) | TW200539855A (enExample) |
| WO (3) | WO2005089808A2 (enExample) |
| ZA (1) | ZA200607705B (enExample) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SV2007002227A (es) * | 2004-09-10 | 2007-03-20 | Wyeth Corp | Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637 |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP1957097A1 (en) * | 2005-12-06 | 2008-08-20 | Wyeth a Corporation of the State of Delaware | Interleukin-11 compositions and methods of use |
| DK2368914T3 (en) | 2006-03-10 | 2019-03-04 | Wyeth Llc | Anti-5T4 antibodies and uses thereof |
| CY1112212T1 (el) * | 2008-04-24 | 2015-12-09 | Immatics Biotechnologies Gmbh | Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια |
| EP2113253B1 (en) * | 2008-04-30 | 2010-03-31 | Immatics Biotechnologies GmbH | Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines |
| AR076284A1 (es) | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
| EP2493506B1 (en) * | 2009-10-30 | 2019-04-10 | Janssen Biotech, Inc. | Il-17a antagonists |
| EP2637692A4 (en) | 2010-11-12 | 2014-09-10 | Scott & White Healthcare | ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8 |
| US9540443B2 (en) | 2011-01-26 | 2017-01-10 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies |
| MX393973B (es) | 2011-05-08 | 2025-03-24 | Legochem Biosciences Inc | Conjugados de proteína-agente activo y método para su preparación. |
| RU2011132483A (ru) * | 2011-08-02 | 2013-02-10 | Елена Александровна Моренко | Биологически активный продукт для применения в ветеринарии и животноводстве, способ его получения и способы повышения выживаемости, стимуляции роста, иммуностимуляции и повышения общей неспецифической резистентности организма сельскохозяйственных животных |
| CN110078827A (zh) | 2012-04-27 | 2019-08-02 | 西托姆克斯治疗公司 | 结合表皮生长因子受体的可活化的抗体其使用方法 |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| HK1210192A1 (en) | 2012-07-19 | 2016-04-15 | Alethia Biotherapeutics Inc. | Anti-siglec-15 antibodies |
| NZ630363A (en) | 2012-07-25 | 2018-09-28 | Celldex Therapeutics Inc | Anti-kit antibodies and uses thereof |
| JP6847388B2 (ja) | 2013-03-15 | 2021-03-31 | レゲネロン ファーマシューティカルス，インコーポレーテッド | 生物活性分子、そのコンジュゲート、及び治療用途 |
| BR112016004023A2 (pt) | 2013-08-26 | 2022-11-16 | Regeneron Pharma | Composição, métodos para preparar uma composição e para tratar uma doença, e, composto |
| WO2015066279A2 (en) | 2013-10-30 | 2015-05-07 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| WO2015089283A1 (en) | 2013-12-11 | 2015-06-18 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
| JP6632984B2 (ja) | 2014-03-11 | 2020-01-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗ＥＧＦＲｖＩＩＩ抗体およびその使用 |
| BR112017020149A8 (pt) | 2015-03-27 | 2023-05-02 | Regeneron Pharma | Derivados de maitansinoide, conjugados dos mesmos e métodos de uso |
| CA2990206A1 (en) * | 2015-06-29 | 2017-01-05 | William Marsh Rice University | Total synthesis of shishijimicin a and analogs thereof |
| IL296285A (en) | 2015-07-06 | 2022-11-01 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| EP3365025B1 (en) | 2015-10-20 | 2020-07-15 | Genentech, Inc. | Calicheamicin-antibody-drug conjugates and methods of use |
| US20170189548A1 (en) * | 2015-11-25 | 2017-07-06 | Immunogen, Inc. | Pharmaceutical formulations and methods of use thereof |
| AU2016359230B2 (en) | 2015-11-25 | 2020-04-23 | Ligachem Biosciences Inc. | Conjugates comprising self-immolative groups and methods related thereto |
| MA43416A (fr) | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
| BR112018014759B1 (pt) | 2016-01-25 | 2024-02-27 | Regeneron Pharmaceuticals, Inc | Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso |
| WO2017160954A1 (en) | 2016-03-15 | 2017-09-21 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
| CN105726527B (zh) * | 2016-03-25 | 2018-05-11 | 苏州大学 | 小分子化合物的用途及其组合物 |
| EP3448891A1 (en) | 2016-04-28 | 2019-03-06 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| WO2017210621A1 (en) | 2016-06-03 | 2017-12-07 | Seattle Genetics, Inc. | Combination of cd33 antibody drug conjugates with chemotherapeutic agents |
| WO2017214433A1 (en) | 2016-06-09 | 2017-12-14 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with flt3 inhibitors |
| EP3478324A1 (en) | 2016-07-01 | 2019-05-08 | GlaxoSmithKline Intellectual Property (No.2) Limited | Antibody-drug conjugates and therapeutic methods using the same |
| JP7066690B2 (ja) | 2016-09-23 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｍｕｃ１６（ムチン１６）抗体 |
| MY199468A (en) | 2016-09-23 | 2023-10-31 | Regeneron Pharma | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof |
| ES3046537T3 (en) | 2016-11-08 | 2025-12-02 | Regeneron Pharma | Steroids and protein-conjugates thereof |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| KR102085798B1 (ko) | 2016-12-28 | 2020-03-06 | 주식회사 인투셀 | 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물 |
| KR20200007905A (ko) | 2017-05-18 | 2020-01-22 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| WO2018213082A1 (en) | 2017-05-18 | 2018-11-22 | Regeneron Pharmaceuticals, Inc. | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof |
| DK3635009T3 (da) | 2017-06-07 | 2026-03-30 | Regeneron Pharma | Sammensætninger og fremgangsmåder til internalisering af enzymer |
| MX2020004691A (es) | 2017-11-07 | 2020-08-20 | Regeneron Pharma | Enlazadores hidrofilicos para conjugados anticuerpo-farmaco. |
| SG11202006510XA (en) | 2018-01-08 | 2020-08-28 | Regeneron Pharma | Steroids and antibody-conjugates thereof |
| KR102871690B1 (ko) | 2018-04-30 | 2025-10-16 | 리제너론 파마슈티칼스 인코포레이티드 | Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도 |
| CN118955710A (zh) | 2018-05-09 | 2024-11-15 | 里珍纳龙药品有限公司 | 抗msr1抗体及其使用方法 |
| BR112020023145A2 (pt) | 2018-05-17 | 2021-02-02 | Regeneron Pharmaceuticals, Inc. | anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto |
| PL3710485T3 (pl) * | 2018-05-30 | 2021-09-13 | Abbvie Stemcentrx Llc | Koniugaty lek-przeciwciało anty-sez6 i sposoby ich stosowania |
| IL283313B2 (en) | 2018-11-20 | 2025-08-01 | Regeneron Pharma | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists |
| JP7590328B2 (ja) | 2018-12-21 | 2024-11-26 | レゲネロン ファーマシューティカルス，インコーポレーテッド | ツブリシン及びタンパク質－ツブリシンコンジュゲート |
| PH12021551476A1 (en) | 2018-12-21 | 2022-04-25 | Regeneron Pharma | Rifamycin analogs and antibody-drug conjugates thereof |
| BR112021013464A2 (pt) | 2019-01-08 | 2021-09-21 | Regeneron Pharmaceuticals, Inc. | Ligantes sem traço e conjugados de proteína dos mesmos |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| CA3128519A1 (en) | 2019-02-21 | 2020-08-27 | Regeneron Pharmaceuticals, Inc. | Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met |
| JP2022530482A (ja) | 2019-05-02 | 2022-06-29 | レゴケム バイオサイエンシズ， インク． | トリス構造を有するリンカーを含むリガンド―薬物複合体 |
| GB201910899D0 (en) * | 2019-07-31 | 2019-09-11 | Scancell Ltd | Binding members |
| AU2020349462A1 (en) | 2019-09-16 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging |
| US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
| JP2023511956A (ja) | 2020-01-24 | 2023-03-23 | レゲネロン ファーマシューティカルス，インコーポレーテッド | タンパク質－抗ウイルス化合物コンジュゲート |
| KR20220148200A (ko) | 2020-02-28 | 2022-11-04 | 리제너론 파마슈티칼스 인코포레이티드 | Her2에 결합하는 이중특이적 항원 결합 분자 및 이의 사용 방법 |
| CN115968304A (zh) | 2020-04-16 | 2023-04-14 | 瑞泽恩制药公司 | 狄尔斯-阿尔德缀合方法 |
| WO2021262910A2 (en) | 2020-06-24 | 2021-12-30 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
| CN116390771A (zh) | 2020-07-13 | 2023-07-04 | 瑞泽恩制药公司 | 与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途 |
| CA3191304A1 (en) | 2020-09-14 | 2022-03-17 | Amy Han | Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof |
| JP2023541133A (ja) * | 2020-09-14 | 2023-09-28 | アムジエン・インコーポレーテツド | 凍結乾燥タンパク質製剤を作製する方法 |
| CA3190569A1 (en) | 2020-10-22 | 2022-04-28 | Christopher Daly | Anti-fgfr2 antibodies and methods of use thereof |
| EP4000635A1 (en) * | 2020-11-16 | 2022-05-25 | Frank J. Hernandez | Therapeutic-oligonucleotides activated by nucleases |
| CA3220081A1 (en) | 2021-07-28 | 2023-02-02 | Thomas Nittoli | Protein-antiviral compound conjugates |
| US20230414775A1 (en) | 2021-12-29 | 2023-12-28 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
| CA3241734A1 (en) | 2022-01-12 | 2023-07-20 | Amy Han | Camptothecin analogs conjugated to a glutamine residue in a protein, and their use |
| AU2023208050A1 (en) | 2022-01-14 | 2024-07-04 | Regeneron Pharmaceuticals, Inc. | Verrucarin a derivatives and antibody drug conjugates thereof |
| KR20230132640A (ko) | 2022-03-04 | 2023-09-15 | 앱티스 주식회사 | 티올 반응성 에디티브를 이용한 항체-약물 컨쥬게이트의 제조 수율을 높이는 방법 |
| JP2025512735A (ja) | 2022-03-11 | 2025-04-22 | リジェネロン ファーマシューティカルズ，インク． | Ｇｌｐ１ペプチド模倣体を含む抗ｇｌｐ１ｒ抗体係留型薬物コンジュゲートおよびその使用 |
| AU2023297610A1 (en) | 2022-06-27 | 2025-01-09 | Trioar, Inc. | Novel linker compound and ligand-drug conjugate therefor |
| JP2025525296A (ja) | 2022-06-27 | 2025-08-05 | トライオール インコーポレイテッド | 自壊性基を含む化合物及びそれを含むリガンド－薬物コンジュゲート |
| CN120239705A (zh) | 2022-07-21 | 2025-07-01 | 萤火虫生物股份有限公司 | 糖皮质激素受体激动剂和其缀合物 |
| KR20240125071A (ko) | 2022-11-01 | 2024-08-19 | 앱티스 주식회사 | Fc 결합성 유닛을 포함하는 화합물 및 이를 이용하여 제조된 컨쥬게이트 |
| WO2024118785A2 (en) | 2022-11-30 | 2024-06-06 | Regeneron Pharmaceuticals, Inc. | Tlr7 agonists and antibody-drug-conjugates thereof |
| WO2024138000A1 (en) | 2022-12-21 | 2024-06-27 | Regeneron Pharmaceuticals, Inc. | Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof |
| WO2024168199A1 (en) | 2023-02-09 | 2024-08-15 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates via inverse electron demand diels-alder reactions |
| WO2024229105A1 (en) | 2023-05-02 | 2024-11-07 | Regeneron Pharmaceuticals, Inc. | Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells |
| CN121568720A (zh) | 2023-07-10 | 2026-02-24 | 瑞泽恩制药公司 | 抗人类cacng1抗体-药物缀合物及其用途 |
| US20250171516A1 (en) | 2023-11-03 | 2025-05-29 | Regeneron Pharmaceuticals, Inc. | Peptide acids as a glp1r agonist and antibody-drug conjugates thereof |
| WO2025117727A1 (en) | 2023-11-29 | 2025-06-05 | Regeneron Pharmaceuticals, Inc. | Analogs of quinoxaline/quinoline cytotoxins, linker- payloads, protein-drug conjugates, and uses thereof |
| US20260078179A1 (en) | 2024-07-18 | 2026-03-19 | Novarock Biotherapeutics, Ltd. | Cdh17 antibodies and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5822085B2 (ja) * | 1977-07-19 | 1983-05-06 | 株式会社ミドリ十字 | 静注用ガンマ・グロブリン製剤 |
| US4675187A (en) * | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| US4554162A (en) * | 1984-05-04 | 1985-11-19 | Warner-Lambert Company | CL-1724 Antibiotic compounds, their production and use |
| US4539203A (en) * | 1984-11-13 | 1985-09-03 | Warner-Lambert Company | CL-1577D And CL-1577E antibiotic/antitumor compounds, their production and use |
| US4970198A (en) * | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
| US5108912A (en) * | 1987-01-30 | 1992-04-28 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
| US5037651A (en) * | 1987-01-30 | 1991-08-06 | American Cyanamid Company | Dihydro derivatives of LL-E33288 antibiotics |
| US5079233A (en) * | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
| US5182192A (en) * | 1987-03-27 | 1993-01-26 | The Wistar Institute | Monoclonal antibodies against glycolipid antigens, methods of producing these antibodies, and use therefor |
| US4971792A (en) * | 1987-03-27 | 1990-11-20 | The Wistar Institute | Monoclonal antibodies against glycolipid antigens |
| US4837206A (en) * | 1987-04-29 | 1989-06-06 | Bristol-Myers Company | Esperamicin derivatives |
| US5053394A (en) * | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| US5606040A (en) * | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| JPH01146826A (ja) * | 1987-12-03 | 1989-06-08 | Nippon Kayaku Co Ltd | 白金化合物の凍結乾燥製剤 |
| IL94872A (en) * | 1989-06-30 | 1995-03-30 | Oncogen | Monoclonal or chimeric antibodies reactive with human carcinomas, recombinant proteins comprising their antigen binding region, pharmaceutical compositions and kits comprising said antibodies and methods for imaging human carcinoma using same |
| US6020145A (en) * | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
| US5980896A (en) * | 1989-06-30 | 1999-11-09 | Bristol-Myers Squibb Company | Antibodies reactive with human carcinomas |
| DK0528767T3 (da) * | 1991-08-21 | 2000-04-17 | Novartis Ag | antistofderivater |
| US6310185B1 (en) * | 1994-03-08 | 2001-10-30 | Memorial Sloan Kettering Cancer Center | Recombinant human anti-Lewis Y antibodies |
| US5773001A (en) * | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| JP3687993B2 (ja) * | 1994-06-24 | 2005-08-24 | シスメックス株式会社 | インシュリン標準液 |
| US5792456A (en) * | 1994-08-04 | 1998-08-11 | Bristol-Myers Squibb Company | Mutant BR96 antibodies reactive with human carcinomas |
| US5714586A (en) * | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) * | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| WO1997013529A1 (en) * | 1995-10-13 | 1997-04-17 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Immunotoxin containing a disulfide-stabilized antibody fragment |
| DK1071700T3 (da) * | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| AU2002213357A1 (en) * | 2000-10-20 | 2002-05-06 | Idec Pharmaceuticals Corporation | Variant igg3 rituxan r and therapeutic use thereof |
| NZ571596A (en) * | 2001-08-03 | 2010-11-26 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| ES2411007T3 (es) * | 2001-10-10 | 2013-07-04 | Novo Nordisk A/S | Remodelación y glicoconjugación de péptidos |
| SG187991A1 (en) * | 2002-05-02 | 2013-03-28 | Wyeth Corp | Calicheamicin derivative-carrier conjugates |
| EP2248892B1 (en) * | 2003-01-22 | 2015-04-22 | Roche Glycart AG | Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function |
| SV2007002227A (es) * | 2004-09-10 | 2007-03-20 | Wyeth Corp | Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637 |
-
2005
- 2005-03-14 AR ARP050100978A patent/AR048098A1/es not_active Application Discontinuation
- 2005-03-14 TW TW094107641A patent/TW200539855A/zh unknown
- 2005-03-15 CA CA002559658A patent/CA2559658A1/en not_active Abandoned
- 2005-03-15 CA CA002558737A patent/CA2558737A1/en not_active Abandoned
- 2005-03-15 PE PE2005000295A patent/PE20060077A1/es not_active Application Discontinuation
- 2005-03-15 WO PCT/US2005/008508 patent/WO2005089808A2/en not_active Ceased
- 2005-03-15 WO PCT/US2005/008505 patent/WO2005089807A2/en not_active Ceased
- 2005-03-15 US US10/592,438 patent/US20070213511A1/en not_active Abandoned
- 2005-03-15 WO PCT/US2005/008509 patent/WO2005089809A2/en not_active Ceased
- 2005-03-15 RU RU2006131599/15A patent/RU2006131599A/ru unknown
- 2005-03-15 AU AU2005222635A patent/AU2005222635A1/en not_active Abandoned
- 2005-03-15 EP EP05732928A patent/EP1725265A2/en not_active Withdrawn
- 2005-03-15 SV SV2005002050A patent/SV2006002050A/es not_active Application Discontinuation
- 2005-03-15 BR BRPI0508824-0A patent/BRPI0508824A/pt not_active IP Right Cessation
- 2005-03-15 BR BRPI0508860-7A patent/BRPI0508860A/pt not_active Application Discontinuation
- 2005-03-15 CN CNA2005800084294A patent/CN1997397A/zh not_active Withdrawn
- 2005-03-15 JP JP2007504018A patent/JP2007529536A/ja not_active Withdrawn
- 2005-03-15 CN CNA2005800084843A patent/CN1997398A/zh active Pending
- 2005-03-15 KR KR1020067021324A patent/KR20060130737A/ko not_active Withdrawn
- 2005-03-15 US US10/592,859 patent/US20070190060A1/en not_active Abandoned
- 2005-03-15 EP EP05732491A patent/EP1725264A2/en not_active Withdrawn
- 2005-03-15 MX MXPA06010556A patent/MXPA06010556A/es unknown
- 2005-03-15 AU AU2005222633A patent/AU2005222633A1/en not_active Abandoned
- 2005-03-15 MX MXPA06010555A patent/MXPA06010555A/es unknown
- 2005-03-15 PA PA20058626201A patent/PA8626201A1/es unknown
- 2005-03-15 US US11/080,587 patent/US20060002942A1/en not_active Abandoned
- 2005-03-15 JP JP2007504017A patent/JP2007529535A/ja not_active Withdrawn
- 2005-03-15 EP EP05725579A patent/EP1740216A2/en not_active Withdrawn
- 2005-03-15 GT GT200500054A patent/GT200500054A/es unknown
- 2005-03-15 AU AU2005222634A patent/AU2005222634A1/en not_active Abandoned
- 2005-03-15 CA CA002557866A patent/CA2557866A1/en not_active Abandoned
-
2006
- 2006-08-31 IL IL177842A patent/IL177842A0/en unknown
- 2006-09-13 CR CR8620A patent/CR8620A/es not_active Application Discontinuation
- 2006-09-13 NO NO20064128A patent/NO20064128L/no not_active Application Discontinuation
- 2006-09-14 ZA ZA200607705A patent/ZA200607705B/xx unknown
- 2006-09-15 EC EC2006006851A patent/ECSP066851A/es unknown
-
2008
- 2008-08-04 US US12/221,551 patent/US20090105461A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007529536A5 (enExample) | ||
| ES2296928T3 (es) | Receptores x hepaticos. | |
| US20100098636A1 (en) | Compositions for Delivery of Therapeutics and Other Materials | |
| JP2011500725A5 (enExample) | ||
| EP1184366A4 (en) | Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha(ppar) | |
| JP2008505985A5 (enExample) | ||
| JP2003531148A5 (enExample) | ||
| JP2009537143A5 (enExample) | ||
| JP2009507833A5 (enExample) | ||
| JP2019532928A5 (enExample) | ||
| JP2007500222A5 (enExample) | ||
| ES2328966T3 (es) | Uso de conjugados de acido biliar o sal biliar con acido graso. | |
| JP2005529192A (ja) | デンプン誘導体、デンプン／活性物質コンジュゲート、その調製方法および薬物としての使用 | |
| JPWO2021049504A5 (enExample) | ||
| PT88648A (pt) | Process for the preparation of new androstane 17-carboxylic acid esters and a pharmaceutical composition containing same | |
| CN106866772B (zh) | 一种胆固醇分子探针及其制备方法和应用 | |
| EP2279752A3 (en) | Conjugates of hydroxyalkyl starch and a protein, prepared by native chemical ligation | |
| CN109422793A (zh) | 一种联合提取猪去氧胆酸与鹅去氧胆酸的方法 | |
| JPH0368542A (ja) | ヘテロ二官能性化合物、およびカルボキシル基含有化合物をアミノ基含有化合物と結合する方法 | |
| CN105646446B (zh) | 一种纯化阿格列汀的方法 | |
| WO2019200293A1 (en) | Ceramide-like lipid-based delivery vehicles and uses thereof | |
| JP4718444B2 (ja) | シクロブタン−１，１−ジカルボキシレートリガンドを有する白金錯体の蛋白結合誘導体 | |
| CN1210310C (zh) | 一种n－乳糖酰壳聚糖 | |
| JP2005029789A5 (enExample) | ||
| MY148416A (en) | Amine salt of carbostyril derivative |